S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.42 (+0.90%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
DIS   130.26 (-0.48%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.42 (+0.90%)
AAPL   240.51 (+1.73%)
FB   189.75 (+2.10%)
MSFT   138.39 (+0.71%)
GOOGL   1,244.23 (-0.01%)
AMZN   1,785.67 (+1.60%)
CGC   20.35 (+0.69%)
NVDA   196.11 (+2.95%)
MU   45.25 (+4.09%)
BABA   173.52 (+2.60%)
TSLA   253.46 (-1.36%)
AMD   32.07 (+3.52%)
T   38.23 (-0.62%)
F   9.03 (-2.80%)
NFLX   278.05 (+1.00%)
BAC   31.02 (+2.21%)
DIS   130.26 (-0.48%)
Log in

Eiger Biopharmaceuticals Stock Price, News & Analysis (NASDAQ:EIGR)

$10.62
-0.43 (-3.89 %)
(As of 10/21/2019 04:00 PM ET)
Today's Range
$10.59
Now: $10.62
$11.84
50-Day Range
$9.73
MA: $10.83
$12.25
52-Week Range
$8.40
Now: $10.62
$15.33
Volume29,790 shs
Average Volume83,686 shs
Market Capitalization$259.66 million
P/E RatioN/A
Dividend YieldN/A
Beta1.02
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EIGR
CUSIPN/A
Phone650-272-6138

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.49 per share

Profitability

Net Income$-52,390,000.00

Miscellaneous

Employees18
Market Cap$259.66 million
Next Earnings Date11/8/2019 (Estimated)
OptionableNot Optionable

Receive EIGR News and Ratings via Email

Sign-up to receive the latest news and ratings for EIGR and its competitors with MarketBeat's FREE daily newsletter.


Eiger Biopharmaceuticals (NASDAQ:EIGR) Frequently Asked Questions

What is Eiger Biopharmaceuticals' stock symbol?

Eiger Biopharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR."

How were Eiger Biopharmaceuticals' earnings last quarter?

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) announced its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($0.75) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.73) by $0.02. View Eiger Biopharmaceuticals' Earnings History.

When is Eiger Biopharmaceuticals' next earnings date?

Eiger Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for Eiger Biopharmaceuticals.

What price target have analysts set for EIGR?

6 brokers have issued 12 month target prices for Eiger Biopharmaceuticals' stock. Their predictions range from $10.72 to $47.00. On average, they expect Eiger Biopharmaceuticals' stock price to reach $31.62 in the next twelve months. This suggests a possible upside of 197.7% from the stock's current price. View Analyst Price Targets for Eiger Biopharmaceuticals.

What is the consensus analysts' recommendation for Eiger Biopharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger Biopharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eiger Biopharmaceuticals.

What are Wall Street analysts saying about Eiger Biopharmaceuticals stock?

Here are some recent quotes from research analysts about Eiger Biopharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company which develops and manufactures drugs and therapies for the treatment of orphan diseases. Eiger BioPharmaceuticals, Inc., formerly known as Celladon Corporation, is based in Palo Alto, California. " (8/13/2019)
  • 2. LADENBURG THALM/SH SH analysts commented, "We believe its cash is sufficient to fund operations through profitability in 2022, assuming it nets ~$50M for its after splitting it with the Progeria Research Foundation. While the last four months the news flow from Eiger’s HDV and progeria programs has been quiet, the next four months include several catalysts in these programs." (8/12/2019)

Has Eiger Biopharmaceuticals been receiving favorable news coverage?

Media headlines about EIGR stock have trended somewhat positive this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eiger Biopharmaceuticals earned a news impact score of 0.8 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Eiger Biopharmaceuticals.

Are investors shorting Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 773,200 shares, an increase of 8.7% from the August 30th total of 711,400 shares. Based on an average daily volume of 118,200 shares, the short-interest ratio is currently 6.5 days. Currently, 3.6% of the shares of the company are sold short. View Eiger Biopharmaceuticals' Current Options Chain.

Who are some of Eiger Biopharmaceuticals' key competitors?

What other stocks do shareholders of Eiger Biopharmaceuticals own?

Who are Eiger Biopharmaceuticals' key executives?

Eiger Biopharmaceuticals' management team includes the folowing people:
  • Mr. David A. Cory R.Ph, MBA, Bus. Founder, Pres, CEO & Director (Age 55)
  • Dr. Jeffrey S. Glenn, Founder, Scientific Advisor & Director (Age 56)
  • Dr. David Apelian, COO, Exec. Medical Officer & Director (Age 54)
  • Mr. James P. Shaffer, Chief Bus. Officer (Age 52)
  • Mr. Sriram Ryali M.B.A., Chief Financial Officer (Age 38)

How do I buy shares of Eiger Biopharmaceuticals?

Shares of EIGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eiger Biopharmaceuticals' stock price today?

One share of EIGR stock can currently be purchased for approximately $10.62.

How big of a company is Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals has a market capitalization of $259.66 million. The biotechnology company earns $-52,390,000.00 in net income (profit) each year or ($3.82) on an earnings per share basis. Eiger Biopharmaceuticals employs 18 workers across the globe.View Additional Information About Eiger Biopharmaceuticals.

What is Eiger Biopharmaceuticals' official website?

The official website for Eiger Biopharmaceuticals is http://www.eigerbio.com/.

How can I contact Eiger Biopharmaceuticals?

Eiger Biopharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The biotechnology company can be reached via phone at 650-272-6138 or via email at [email protected]


MarketBeat Community Rating for Eiger Biopharmaceuticals (NASDAQ EIGR)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  359 (Vote Outperform)
Underperform Votes:  247 (Vote Underperform)
Total Votes:  606
MarketBeat's community ratings are surveys of what our community members think about Eiger Biopharmaceuticals and other stocks. Vote "Outperform" if you believe EIGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EIGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel